Reuters logo
BRIEF-Allergan issues statement on Namenda XR patent litigation following announcement of ANDA approvals
September 29, 2016 / 1:42 PM / a year ago

BRIEF-Allergan issues statement on Namenda XR patent litigation following announcement of ANDA approvals

Sept 29 (Reuters) - Allergan Plc

* Company has not announced any earlier licensed entry dates

* Company has settled with all other Namenda XR ANDA defendants, including Lupin Limited and Lupin Pharmaceuticals Inc

* If district court ruling on patents is upheld, there is a possibility that generic entry for Namenda XR could occur

* Company will defend validity of the patents on appeal and believes that its arguments on appeal are substantial and meritorious Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below